title: PET/Computed Tomography in Neuroendocrine Tumor: Value to Patient Management and Survival Outcomes.
abstract: PET/computed tomography evaluation of neuroendocrine tumors is gaining prominence with the availability of novel pet radiotracers, such as (18)F-DOPA and gallium 68 somatostatin peptide derivatives. These tumors have unique properties and hence the basis of use of these new radiotracers. Prominent centers worldwide have reported the usefulness of these PET tracers in diagnosis and clinical decision making. Portability of 68Ge/68Ga generators has also helped in more widespread use of these somatostatin peptide derivatives as PET radiotracers. This article reviews established and potential roles of these novel PET radiotracers in diagnosis, management, and prognosis of neuroendocrine tumors.
authors.affiliation: Therapeutic Nuclear Medicine Division, Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi 110029, India.
authors.forename: Shamim Ahmed
authors.initials: SA
authors.lastname: Shamim
authors.affiliation: Diagnostic Nuclear Medicine Division, Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi 110029, India.
authors.forename: Abhishek
authors.initials: A
authors.lastname: Kumar
authors.affiliation: Diagnostic Nuclear Medicine Division, Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi 110029, India. Electronic address: rkphulia@yahoo.com.
authors.forename: Rakesh
authors.initials: R
authors.lastname: Kumar
mesh_terms: D000310:Adrenal Gland Neoplasms / Q000000981:diagnostic imaging / Q000532:radiotherapy; D004295:Dihydroxyphenylalanine / Q000031:analogs & derivatives; D019788:Fluorodeoxyglucose F18; D005710:Gallium Radioisotopes; D005770:Gastrointestinal Neoplasms / Q000000981:diagnostic imaging / Q000532:radiotherapy; D006801:Humans; D064847:Multimodal Imaging / Q000379:methods*; D018358:Neuroendocrine Tumors / Q000000981:diagnostic imaging / Q000532:radiotherapy; D010190:Pancreatic Neoplasms / Q000000981:diagnostic imaging / Q000532:radiotherapy; D010235:Paraganglioma / Q000000981:diagnostic imaging / Q000532:radiotherapy; D010673:Pheochromocytoma / Q000000981:diagnostic imaging / Q000532:radiotherapy; D049268:Positron-Emission Tomography / Q000379:methods*; D011379:Prognosis; D019275:Radiopharmaceuticals; D011878:Radiotherapy / Q000379:methods; D013964:Thyroid Neoplasms / Q000000981:diagnostic imaging / Q000532:radiotherapy; D014057:Tomography, X-Ray Computed / Q000379:methods*
chemical_list: D005710:Gallium Radioisotopes; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; C043437:fluorodopa F 18; D004295:Dihydroxyphenylalanine
keywords: (18)F-DOPA; (18)F-FDG; (68)Ga-DOTANOC; Medullary thyroid cancer; Neuroendocrine tumors; PET/CT; Paraganglioma; Pheochromocytoma